Monoclonal antibodies to basic fibroblast growth factor
US8101725B2 · kind B2 · utility
1Cited by
2References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 28, 2009 |
| Grant date | Jan 24, 2012 |
| Priority date | — |
| Expiry date | May 28, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.